April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Patient Persistency With Topical Glaucoma Therapy is Higher With Fixed Dose Brimonidine/Timolol Than With Two-Bottle Combinations
Author Affiliations & Notes
  • G. F. Schwartz
    Glaucoma Consultants, Baltimore, Maryland
  • V. D. Patel
    Allergan, Inc., Irvine, California
  • C. Burk
    Health Outcomes Consultant, Laguna Beach, California
  • T. Bennett
    Wolters Kluwer Pharma Solutions, Phoenix, Arizona
  • Footnotes
    Commercial Relationships  G.F. Schwartz, Pfizer, C; Allergan, C; Pfizer, R; Allergan, R; V.D. Patel, Allergan, E; C. Burk, Allergan, C; T. Bennett, Wolters Kluwer Pharma Solutions, E.
  • Footnotes
    Support  Allergan, Inc.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 185. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G. F. Schwartz, V. D. Patel, C. Burk, T. Bennett; Patient Persistency With Topical Glaucoma Therapy is Higher With Fixed Dose Brimonidine/Timolol Than With Two-Bottle Combinations. Invest. Ophthalmol. Vis. Sci. 2010;51(13):185.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Glaucoma patients often require multiple topical medications to reach target intraocular pressure, and treatment persistence is important. This analysis examined whether persistence differs between patients prescribed topical brimonidine/timolol or 2-bottle combinations.


Sample patients from the Wolters Kluwer Pharma Solutions Source® Lx Database were tracked over time. Glaucoma patients (ICD-9 code 365.xx) were included if they had an index (qualifying) prescription for a product of interest from January-June 2008, but not the 6 months prior to the index prescription. Kaplan-Meier regression analysis was performed to compare medication persistence (switch or discontinue) for 12 months past the index prescription for patients receiving fixed combination of brimonidine (brim)/timolol (n=981) vs a 2-bottle combination. The 2-bottle arms were: beta blocker (BB) + brim (n=561); BB + carbonic anhydrase inhibitor (CAI; acetazolamide, metazolamide, brinzolamide, dorzolamide; n=365); BB + prostaglandin analog (PGA; bimatoprost, latanoprost, travoprost; n=1523); CAI + brim (n=483); CAI + PGA (n=922); and PGA + brim (n=1769).


From Month 3 onwards, a significantly greater proportion of patients remained on fixed combination of brim/timolol vs each of the 2-bottle combinations (Table). Further analysis of patients receiving brim/timolol showed the average number of prescriptions/patient was 7.8, and average time between prescriptions was 44.7 days, consistent with the high persistence.


Persistence with topical glaucoma therapy is higher with fixed combination of brim/timolol than with 2-bottle combinations.  

Keywords: intraocular pressure 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.